Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

Mitosis orchestrates eukaryotic cell division, maintaining genetic fidelity and playing a key role in development, tissue homeostasis, and cancer progression.